Paxil product liability claims
Executive Summary
GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...
You may also be interested in...
Paxil TV Ad Case Could Produce Ruling On FDA’s Authority To Regulate Ads
A suit regarding claims in Paxil TV ads could produce a court ruling regarding FDA's authority to regulate advertising
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.